Theriva Biologics, Inc. (TOVX) Q1 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Theriva Biologics 2023 First Quarter Operational Highlights and Financial Results. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Chris Calabrese of LifeSciAdvisors. Thank you, Chris. You may begin. Thank you, Operator, and good morning, everyone. Welcome to Theriva Biologics' first quarter 2023 investor conference call. Leading the call today will be Stephen Shawcross, Chief Executive and Chief Financial Officer of Theriva Biologics. Dr. Manel Cascaio, General Director of Theriva Biologics, European subsidiary, and Dr. Vince Wachir, Head of Corporate and Product Development of Theriva Biologics, are also on the call and will be available to answer questions during the Q&A session. The REVA Biologics issued a press release this morning, which provided operational highlights and included financial results for the first quarter ending March 31st, 2023. The press release can be found in the investor section of the company website at www.therevabio.com, together with the quarterly report on Form 10-Q for the quarter-ended March 31st, 2023, which we plan to file today with the Securities and Exchange Commission, or SEC. In addition to the phone line, this call is being streamed live via webcast, which will be archived on the company website www.cerevabio.com for 90 days. During the call, certain forward-looking statements regarding Cereva Biologics and VCN Biosciences' current expectations and projections about future events will be made. Generally, th...